168 related articles for article (PubMed ID: 3479419)
1. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients.
Pedersen SS; Jensen T; Hvidberg EF
J Antimicrob Chemother; 1987 Oct; 20(4):575-83. PubMed ID: 3479419
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Jensen T; Pedersen SS; Nielsen CH; Høiby N; Koch C
J Antimicrob Chemother; 1987 Oct; 20(4):585-94. PubMed ID: 3479420
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.
Rubio TT; Miles MV; Lettieri JT; Kuhn RJ; Echols RM; Church DA
Pediatr Infect Dis J; 1997 Jan; 16(1):112-7; discussion 123-6. PubMed ID: 9002120
[TBL] [Abstract][Full Text] [Related]
4. Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses.
Odoul F; Le Guellec C; Giraut C; de Gialluly C; Marchand S; Paintaud G; Saux MC; Rolland JC; Autret-Leca E
Therapie; 2001; 56(5):519-24. PubMed ID: 11806288
[TBL] [Abstract][Full Text] [Related]
5. [A cross-over study on the effectiveness of ofloxacin and ciprofloxacin administered orally].
Kurz CC; Marget W; Harms K; Bertele RM
Infection; 1986; 14 Suppl 1():S82-6. PubMed ID: 2937740
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
[TBL] [Abstract][Full Text] [Related]
7. Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.
LeBel M
Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):316-24. PubMed ID: 1907546
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
Wise R; Griggs D; Andrews JM
Rev Infect Dis; 1988; 10 Suppl 1():S83-9. PubMed ID: 3162327
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
10. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.
Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL
Drugs; 1987; 34 Suppl 1():159-69. PubMed ID: 3481317
[TBL] [Abstract][Full Text] [Related]
11. A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa.
Madaras-Kelly KJ; Larsson AJ; Rotschafer JC
J Antimicrob Chemother; 1996 Apr; 37(4):703-10. PubMed ID: 8722536
[TBL] [Abstract][Full Text] [Related]
12. Levofloxacin pharmacokinetics in adult cystic fibrosis.
Lee CKK; Boyle MP; Diener-West M; Brass-Ernst L; Noschese M; Zeitlin PL
Chest; 2007 Mar; 131(3):796-802. PubMed ID: 17356095
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.
Schaefer HG; Stass H; Wedgwood J; Hampel B; Fischer C; Kuhlmann J; Schaad UB
Antimicrob Agents Chemother; 1996 Jan; 40(1):29-34. PubMed ID: 8787874
[TBL] [Abstract][Full Text] [Related]
14. Comparative crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin and ofloxacin.
Echols R; Weinstein MP; O'Keeffe B; Shah A; Heller AH
J Antimicrob Chemother; 1994 Jan; 33(1):111-8. PubMed ID: 8157551
[TBL] [Abstract][Full Text] [Related]
15. Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis.
Goldfarb J; Stern RC; Reed MD; Yamashita TS; Myers CM; Blumer JL
Am J Med; 1987 Apr; 82(4A):174-9. PubMed ID: 3555032
[TBL] [Abstract][Full Text] [Related]
16. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
Stass H; Delesen H; Nagelschmitz J; Staab D
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
[TBL] [Abstract][Full Text] [Related]
17. Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers.
Zeiler HJ; Beermann D; Wingender W; Förster D; Schacht P
Infection; 1988; 16 Suppl 1():S19-23. PubMed ID: 3286510
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis.
Jensen T; Pedersen SS; Høiby N; Koch C
Eur J Clin Microbiol; 1987 Dec; 6(6):618-22. PubMed ID: 3326741
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis.
Smith MJ; White LO; Bowyer H; Willis J; Hodson ME; Batten JC
Antimicrob Agents Chemother; 1986 Oct; 30(4):614-6. PubMed ID: 3789695
[TBL] [Abstract][Full Text] [Related]
20. Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis.
Goldfarb J; Wormser GP; Inchiosa MA; Guideri G; Diaz M; Gandhi R; Goltzman C; Mascia AV
J Clin Pharmacol; 1986 Mar; 26(3):222-6. PubMed ID: 2937812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
